Skip to main content

Table 3 Association among serum lipids and clinicopathological parameters and surgical outcomes

From: Integrated analysis of serum lipid profile for predicting clinical outcomes of patients with malignant biliary tumor

  TC/HDL ApoB, g/L Lipoprotein, g/L
≤ 10.08
(n = 187)
> 10.08
(n = 65)
p ≤ 0.9
(n = 87)
> 0.9
(n = 165)
p ≤ 72
(n = 141)
> 72
(n = 111)
p
Clinicopathological characteristics
 Tumor type    < 0.001    < 0.001    0.004
 GBC 64(34.2) 2(3.1) < 0.001 30(34.5) 36(21.8) 0.030 32(22.7) 34(30.6) 0.155
 ICC 42(22.5) 5(7.7) 0.008 25(28.7) 22(13.3) 0.003 20(14.2) 27(24.3) 0.040
 ECC 81(43.3) 58(89.2) < 0.001 32(36.8) 107(64.8) < 0.001 89(63.1) 50(45.0) 0.004
 BMI ≥ 23 kg/m2 122(65.2) 3(4.6) < 0.001 57(65.5) 68(41.2) < 0.001 59(41.8) 66(59.5) 0.005
 Alcohol 40(21.4) 21(32.3) 0.077 17(19.5) 44(26.7) 0.209 32(22.7) 29(26.1) 0.528
 Fatty liver 8(4.3) 5(7.7) 0.455 2(2.3) 11(6.7) 0.234 9(6.4) 4(3.6) 0.322
 Jaundice 69(36.9) 64(98.5) < 0.001 32(36.8) 101(61.2) < 0.001 87(61.7) 46(41.4) 0.001
 Cardiovascular disease 77(41.2) 25(38.5) 0.701 33(38.0) 69(41.8) 0.550 57(40.4) 45(40.5) 0.985
Tumor size, cm    0.029    0.882    0.637
 d ≤ 2 78(41.7) 34(52.3) 0.139 35(40.2) 77(46.7) 0.328 68(48.2) 44(39.6) 0.173
 2 < d ≤ 3 40(21.4) 19(29.2) 0.198 21(24.1) 38(23.0) 0.843 32(22.7) 27(24.3) 0.762
 3 < d ≤ 4 21(11.2) 6(9.2) 0.653 10(11.5) 17(10.3) 0.771 15(10.6) 12(10.8) 0.965
 d > 4 40(21.4) 4(6.2) 0.005 16(18.4) 28(17.0) 0.778 22(15.6) 22(19.8) 0.381
Lymph node metastasis 58(31.0) 23(35.4) 0.516 25(28.7) 56(33.9) 0.400 42(29.8) 39(35.1) 0.367
Extrahepatic involvement 96(51.3) 62(95.4) < 0.001 42(48.3) 116(70.3) 0.001 100(70.9) 58(52.3) 0.002
Intrahepatic involvement 67(35.8) 14(21.5) 0.034 35(40.2) 46(27.9) 0.046 40(28.4) 41(36.9) 0.148
Gallbladder involvement 69(36.9) 9(13.8) 0.001 36(41.4) 42(25.5) 0.009 39(27.7) 39(35.1) 0.203
TNM    < 0.001    0.018    0.166
 I 69(36.9) 25(38.5) 0.822 32(36.8) 62(37.6) 0.901 52(36.9) 42(37.8) 0.876
 II 43(23.0) 30(46.2) < 0.001 17(19.5) 56(33.9) 0.017 47(33.3) 26(23.4) 0.085
 III 75(40.1) 10(15.4) < 0.001 38(43.7) 47(28.5) 0.015 42(29.8) 43(38.7) 0.136
 High differentiation 62(33.2) 13(20.0) 0.046 25(28.7) 50(30.3) 0.796 39(27.7) 36(32.4) 0.411
 Radical cure 119(63.6) 38(58.5) 0.458 59(67.8) 98(59.4) 0.190 90(63.8) 67(60.4) 0.573
 R0 120(64.2) 39(60.0) 0.548 60(70.0) 99(60.0) 0.161 91(64.5) 68(61.3) 0.592
 CA199 > 37 U/mL 113(60.4) 60(92.3) < 0.001 58(66.7) 115(69.7) 0.622 107(75.9) 66(59.5) < 0.001
Surgical outcome
 Estimated blood loss, mL 300(100–500) 300(200–575) 0.195 300(100–500) 300(200–500) 0.137 400(175–500) 250(150–450) 0.117
 Postoperative hospital days 18.0(14.0–26.0) 23.0(20.0–30.5) < 0.001 18.0(15.0–26.0) 20.5(16.0–28.0) 0.385 20.5(16.0–28.0) 18.0(15.0–27.0) 0.079
 Postoperative complications 57(30.5) 24(36.9) 0.338 29(33.3) 52(31.5) 0.622 52(36.9) 29(26.1) 0.070
 Bleeding 3(1.6) 6(9.2) 0.014 1(1.1) 8(4.8) 0.251 9(6.4) 0(0.0) 0.018
 Infection 29(15.5) 17(26.2) 0.056 13(14.9) 33(20.0) 0.323 32(22.7) 14(12.6) 0.040
 Liver dysfunction 0(0.0) 0(0.0) 0(0.0) 0(0.0) 0(0.0) 0(0.0)
 Bile leakage 3(1.6) 0(0.0) 0.571 0(0.0) 3(1.8) 0.553 0(0.0) 3(2.7) 0.084
 Ascites 17(9.1) 6(9.2) 0.973 10(11.5) 13(7.9) 0.343 14(9.9) 9(8.1) 0.618
 Others 24(12.8) 10(15.4) 0.604 14(16.1) 20(12.1) 0.380 20(14.2) 14(12.6) 0.717
  1. Bold type means P < 0.05
  2. ApoB Apolipoprotein B, BMI Body mass index, CA199 Carbohydrate antigen 199, CC Cholangiocarcinoma, ECC Extrahepatic cholangiocarcinoma, GBC Gallbladder cancer, ICC Intrahepatic cholangiocarcinoma, TC Total cholesterol
  3. Estimated blood loss and postoperative days were expressed as median (interquartile range, IQR)